Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has scheduled a conference call for 29th October 2020 at 8:00 AM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.alexion.com
Earnings Expectation
Alexion Pharmaceuticals, Inc. is expected to report third quarter earnings results, before market open, on Thursday 29th October 2020. Analysts polled by Thomson Reuters anticipate third quarter income of $ 2.60 per share from revenue of $ 1426.24 million. Looking ahead, the full year income are expected at $ 11.30 per share on the revenues of $ 5750.88 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 5,550.00 million ~ $ 5,600.00 million, where as bottomline are predicted in a range of $ 10.65 ~ $ 10.95 per share
Click Here For More Historical Outlooks Of Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
